Bonaventure Equity

Bonaventure Equity operates as a specialized venture capital firm focused on pharmaceutical investing, backing founders who are developing transformative solutions within the life sciences sector. The firm distinguishes itself through a collaborative approach, bringing together partners, founders, and researchers to address complex healthcare challenges, with a particular emphasis on emerging areas such as cannabinoid and psychedelic therapies. Its technical approach centers on identifying and nurturing innovative scientific discoveries with significant market potential.

The firm was founded in 2014 by Ross O'Brien, who serves as Managing Partner, and Bill Kehoe, a co-founder and Managing Partner. Derrick Mayes also holds a co-founder and senior advisor role. Their collective insight recognized the need for a reimagined approach to pharmaceutical investing, especially in underserved niches of life sciences. Bill Kehoe brings extensive experience as a CFO, COO, and M&A finance professional, while Derrick Mayes contributes expertise as an entrepreneur and public/private company board member.

Bonaventure Equity's portfolio companies are led by founders innovating across various life science domains, including novel drug discovery platforms, advanced chemical synthesis, genetic research, and biotech ventures targeting neurological disorders. The firm’s long-term vision is to drive progress in healthcare by identifying and nurturing groundbreaking scientific discoveries. It aims to actively shape the future of pharmaceutical and life sciences innovation by supporting entrepreneurs at the forefront of these fields.